

Assessment of Ischemia modified albumen in chronic liver diseases.

ABSTRACT

Aims: Ischemia modified albumin (IMA) level is increased in ischemic conditions and in diseases such as myocardial infarction, systemic sclerosis, advanced cancer, end-stage renal disease and intrauterine disorders. The role of IMA in chronic liver diseases and its correlation with disease severity needs further investigations. So we aimed to assess IMA and its ratio to albumin as a marker of advanced liver cirrhosis and their correlation with the disease severity.

Study design: A cross sectional study including 125 patients with chronic liver disease (80 males and 45 females) with mean age 54.63 years; and 35 healthy controls.

Place and Duration of Study: Hepatology Unit Specialized Medical Hospital and Tropical Department, Mansoura University between June 2014 and March 2015.

Methodology: The patients with chronic liver disease (80 males, 45 females) with age range from 46 to 62 years, 70 cases were chronic HCV, 15 chronic HBV, 20 combined HCV, HBV 10 autoimmune liver diseases, 5 NASH, and 5 of unknown cause. They were further subdivided according to Child-Pugh scoring into 50 patients with Child A, 45 patients with Child B and 30 patients with Child C. 35 healthy subjects of matched age and sex were included as control group. Laboratory analysis including complete blood count, liver profile, prothrombin time, IMA and IMAR were done to all patients and control.

Results: There was significant increase in IMA and IMAR in studied patient groups versus controls, in Child B versus Child A and in Child C versus both Child A & B. A significant positive correlation was found between both IMA & IMAR with total bilirubin and INR while a significant negative correlation was reported between both IMA & IMAR with albumin, ALT, AST, Hb, WBCs and PLT in liver cirrhosis. At cut off > 0.767 IMA had a sensitivity of 86.99 % and a specificity of 77.1% (AUC; 0.85) and at cut off > 0.213 IMAR had a sensitivity of 92.5 % and a specificity of 88.5% (AUC; 0.95) for detecting liver cirrhosis. For detecting severity of liver cirrhosis, by comparing Child B and Child C, at cut off > 0.968 IMA had a sensitivity of 93.3 % and a specificity of 94.2% (AUC; 0.96) and at cut off > 0.453 IMAR had a sensitivity of 92.8 % and a specificity of 72.7% (AUC; 0.86) for detecting severity of liver cirrhosis.

Conclusion: IMA and IMAR are sensitive markers in chronic liver disease and better correlated with the degree of decompensation. A further study to assess their role in follow up of treatment response is recommended

Keywords: IMA, IMAR, cirrhosis and chronic liver disease

1. INTRODUCTION

Chronic liver disease is a major health problem in Egypt and is commonly associated with HCV and HBV infections [1]. Cirrhosis is often an indolent disease; most of patients remain asymptomatic until the occurrence of decompensation, characterized by ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, or variceal bleeding from portal hypertension. No serologic or radiographic test can accurately diagnose the severity of cirrhosis [2]

Human serum albumin is the most abundant plasma protein, it constitutes about 50% of the total protein content. It is mainly synthesized in liver and it is responsible for about 70% of the plasma oncotic pressure [3] also it has further biological properties: It binds and transports various water-insoluble molecules, metals, and drugs, also shares in detoxification of endogenous and exogenous substances [4]. Furthermore, it is the main circulating antioxidant in the body, being the major extracellular source of reduced sulfhydryl groups [5].

The amino terminal end of albumin molecule is the primary binding site for cobalt and nickel [6]. This site is susceptible to biochemical degradation under various conditions such as ischemia, hypoxia, superoxide-radical injury and acidosis, this decreases binding capacity of albumin for metals and generates variant of albumin with reduced metal binding, known as ischemia modified albumin (IMA) [7].

High serum IMA level was first used as an early marker for the diagnosis of myocardial ischemia and acute coronary syndrome in patients presenting with typical acute chest pain [8]. Also, IMA level is known to increase in other ischemic conditions and in diseases as systemic sclerosis, advanced cancer, end-stage renal disease and intrauterine disorders [7].

Only few studies were done to assess the role of IMA in chronic liver diseases. *Jalan et al*, studied albumin functions in patients with decompensated cirrhosis and reported that albumin functions are impaired in advanced cirrhosis. Additionally, they found that serum IMA level (expressed as an albumin ratio) correlate with the disease severity and may have prognostic use in acute-on-chronic liver failure [9].

So, the aim of this work was to assess IMA and its ratio to albumin as a marker of advanced liver cirrhosis and their correlation with the disease severity

2. Material and Methods

This study was conducted on 125 patients with chronic liver disease, 80 males and 45 females with age range from 46 to 62 years. The diagnosis of chronic liver disease was based on history taking, complete physical examinations, abdominal ultrasound and laboratory investigations including liver profile and hepatitis markers. Patients were excluded if they received albumin infusion one month prior to the involvement in this study, had infection or hepatorenal syndrome, also patients who had malignancy, vascular disease or thrombosis were excluded. 70 cases were chronic HCV, 15 chronic HBV, 20 combined HCV and HBV, 10 autoimmune liver diseases, 5 NASH, and 5 of unknown cause. They were further subdivided according to Child-Pugh scoring into 50 patients with Child A, 45 patients with Child B and 30 patients with Child C. Thirty five healthy subjects, 20 males and 15 females of matched age (46 to 62) were included as control group. All participants signed a consent to be included in the study and the study was approved by Local Ethical Committee of Mansoura Faculty of Medicine

2.1 Sampling:

Seven milliliters venous blood samples were withdrawn and divided as follow; 1ml into EDTA tube for CBC, 1.8 milliliter into prothrombin tube for prothrombin time and INR and the rest into plain tube, left to clot and serum was separated into two aliquots, the first, used for liver and kidney profiles and random blood glucose analysis and the second was stored at -20°C until ischemia modified albumin assay.

2.2 Methods of assay:

Complete blood count was done using automated counter, Sysmex KX-21, USA. Liver and kidney profiles and random blood glucose were performed using Dimension Xpand plus chemistry autoanalyzer, Siemens.

Ischemia modified albumin level was analyzed using the colorimetric method developed by Bar-Or et al, [10]. Two hundred microliter (μ L) of patient serum was placed into glass tubes then 50 μ L of 0.1% $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ (Sigma) was added. After gentle shaking, the mixture was left for 10 minutes to ensure sufficient cobalt albumin binding. Then, 50 μ L of 1.5 mg/mL dithiothreitol (DTT) was added as a coloring agent. After 2 minutes, 1 mL of 0.9% NaCl was added to stop the reaction. A sample blank was prepared for every sample using the same steps as the sample but 50 μ L of distilled water was used instead of 50 μ L of 1.5 mg/mL DTT. Sample absorbancies were measured at 470 against its sample blank. IMA was expressed as unit per milliliter and IMAR was calculated by dividing IMA in U/ml to Albumin in g/dl ($\text{IMA (U/ml)} / \text{albumin (g/dl)}$)

2.3 Statistical Analysis:

Data are expressed as mean $\pm$ SD. Receiver operator characteristic (ROC) curves with respective points of maximal accuracy for sensitivity and specificity were generated to determine the performance of both IMA and IMAR. Tukey's Multiple Comparison Test was used to assess the significance of group differences. Spearman's rank correlation coefficient was used to examine the correlation between the level of IMA and IMAR and other laboratory parameters. $P < 0.05$ was considered to indicate a statistically significant result. Statistical data were analyzed using Graph Pad Prism 5 version 5.01

3. RESULTS AND DISCUSSION

3.1 Results:

Table (1) illustrates some demographic and clinical data of the studied patient groups. Child A included 50 patient (30 males and 20 females) with a mean age of 54.7 ± 4.5 , Child B included 45 patients (30 males and 15 females) with a mean age of 54.9 ± 6.2 and Child C were 30 patients (20 males and 10 females) with a mean age of 56 ± 4.7 , while the control group included 35 subjects (20 males and 15 females) with a mean age of 54.8 ± 5.6 . There was no significant difference in age or sex between studied groups and controls ($p > 0.05$). The causes of chronic liver diseases were chronic HCV in 70 cases (56 %), chronic HBV in 15 cases (12 %), combined chronic HCV and HBV in 20 cases (16 %), autoimmune liver diseases in 10 cases (8 %), NASH in 5 cases (4 %), and 5 cases (4 %) of unknown cause (figure 1)

There was significant increase in total bilirubin, INR, ALT, AST, IMA and IMAR in studied patient groups versus controls while a significant decrease in albumin, Hb, PLT and WBCs were reported in them in comparison to controls (table, 2). By comparing Child B versus Child A, there was significant increase in total bilirubin, INR, AST and ALT and significant decrease in albumin and Hb, while there was no difference in WBCs and PLT.

Also when comparing Child C to both Child B and Child A there was significant increase in total bilirubin, INR, AST and ALT and significant decrease in albumin, WBCs, PLT and Hb

A significant positive correlation was found between both IMA & IMAR with total bilirubin and INR while a significant negative correlation was reported between both IMA & IMAR with albumin, ALT, AST, Hb, WBCs and PLT in liver cirrhosis (table 3 & figure 3).

At cut off > 0.767 IMA had a sensitivity of 86.99 % and a specificity of 77.1% (AUC; 0.85) and at cut off > 0.213 IMAR had a sensitivity of 92.5 % and a specificity of 88.5% (AUC; 0.95) for detecting liver cirrhosis (Figure 4). For detecting severity of liver cirrhosis, by comparing Child B and Child C, at cut off > 0.968 IMA had a sensitivity of 93.3 % and a specificity of 94.2% (AUC; 0.96) and at cut off > 0.453 IMAR had a sensitivity of 92.8 % and a specificity of 72.7% (AUC; 0.86) for detecting severity of liver cirrhosis (figure 5).

3.2 Discussion:

Albumin is more than a volume expander, it has been proved to undertake various functions including metal chelation, fatty acid transport, drug binding and anti-oxidant activity. [4]

Increased IMA suggest an impaired metal chelation capacity and loss of albumin function. Also, increased IMA level was associated with poor survival [11, 12, 9]

IMA was shown to be a myocardial infarction marker [13]. However, IMA may increase in non-cardiac ischemic conditions, as liver cirrhosis and metabolic syndrome [14, 15]. Also, in diabetic patients in chronic hypoxia conditions [16] and in chronic hepatic and renal diseases. [17]

Patients with advanced cirrhosis almost always have hypoalbuminemia [18]. A reduced albumin level will result in a lower capacity to bind cobalt, leading to high false positive IMA score; so it was suggested that IMA should be expressed relative to the serum albumin concentration (IMAR) to minimize the impact of reduced albumin level. [9]

Thus, in this study we aimed to assess IMA and its ratio to albumin IMAR as a marker of advanced liver cirrhosis and their correlation with the disease severity.

The present study that assess the serum IMA and IMAR levels in patients with CLD, revealed that IMA and IMAR levels were significantly higher in these patients compared to healthy subjects. Elevation of IMAR which is considered a marker of albumin function, and impairment of liver functions in patients with CLD not only decreases the effective circulation volume in association with hypoalbuminemia, but also decreases the get rid of toxic metabolites. [19]

This may be explained by oxidative stress which results from CLD and affects the biological properties of albumin, so becomes more susceptible to proteinase digestion and faster degradation than the non-oxidized part, and decreased binding capacity to various substances [4, 20]. In healthy adults, a small fraction is highly oxidized to sulfonic acid (human nonmercaptalbumin 2). In contrast, in chronic diseases, the oxidized form of albumin greatly increases, leading to an impairment of its biological activities [20].

In the current study, it was noticed that IMA and IMAR levels were correlated with Child-Pugh score and similar results were reported by Jalan et al, Chen et al, Cakir et al and Klammt et al [9, 15, 19, 21]. This increase in IMAR levels with disease severity provides evidence of protein modification, which associated with severity of oxidative stress. [22]

Higher level of IMAR in more advanced decompensated cirrhotic patients (Child B,C) may lead to accumulation of toxic metabolites (tryptophan, endogenous benzodiazepines, bile acids, and fatty acids) in these patients, and may aggravate the development of hepatic encephalopathy.

A significant positive correlation was found between both IMA & IMAR with total bilirubin and INR while a significant negative correlation was reported between both IMA & IMAR with albumin, ALT, AST, Hb, WBCs and PLT in liver cirrhosis. This is consistent with its correlation to liver disease severity. Similar results was found by Chen et al which found that IMA and IMAR were significantly correlated with bilirubin and INR in patients with chronic hepatitis and cirrhosis [15]. Also Kumar and Subramanian reported a significant positive correlation between IMAR and bilirubin and a significant negative correlation with albumin. [23]

In contrast Cakir et al found no correlation between serum alanine aminotransferase (ALT), INR levels and serum IMAR level. Only bilirubin level was significantly correlated with serum IMAR level [19]. This difference between that study and the current study can be explained by firstly; more advanced chronic liver disease (larger number of Child B, C) in our study and Child A in the other study. Secondly; different etiologies of liver disease (most of our cases are chronic HCV, HBV and in the other study, 64% metabolic and 18% cholestatic liver diseases).

Table (1): Demographic and clinical data of studied patient groups:

Parameter	Control (n=35)	Child A (n=50)	Child B (n=45)	Child C (n=30)
Age (years)				
Mean $\pm$ SD	54.8 $\pm$ 5.6	54.7 $\pm$ 4.5	54.9 $\pm$ 6.2	56 $\pm$ 4.7
p-value	>0.05			
Sex				
Male	20	30	30	20
Female	15	20	15	10

p-value	>0.05			
Ascites (N0-%)	35 (100%)	50 (100%)	12 (26.6%)	4 (13.3%)
No			33 (73.4%)	6 (20.0%)
Mild				20 (66.7%)
Moderate				
Severe				
Hepatic encephalopathy	No	No	5 (11%)	10 (33.3%)




Figure (1): Causes of chronic liver diseases among studied patients

Table (2): Laboratory parameters of studied patient groups:

Parameter	Control (n=35)	Child A (n=50)	Child B (n=45)	Child C (n=30)	p- value
Hb (gm/dl)					$P_1 < 0.05^*$
Mean $\pm$ SD	13.6 ± 1.2	9.8 ± 0.75	9.0 ± 0.4	7.8 ± 0.41	$P_2 < 0.05^*$
p-value	$< 0.05^*$				$P_3 < 0.05^*$
WBCs ($10^3/\text{cmm}$)					$P_1 > 0.05$
Mean $\pm$ SD	6.1 ± 1.29	3.3 ± 0.43	3.37 ± 0.29	3.0 ± 0.54	$P_2 > 0.05$
p-value	$< 0.05^*$				$P_3 > 0.05$
PLT ($10^3/\text{cmm}$)					$P_1 > 0.05$
Mean $\pm$ SD	221.3 ± 21.6	88.5 ± 8.2	91.2 ± 8.3	71.7 ± 31.5	$P_2 < 0.05^*$
p-value	$< 0.05^*$				$P_3 < 0.05^*$
ALT(U/L)					$P_1 < 0.05^*$

Mean ±SD	22.1 ± 4.6	52.5 ± 6.4	47.8 ± 6.4	35.8 ± 11.0	P ₂ < 0.05*
p-value	< 0.05*				P ₃ < 0.05*
AST (U/L)					P ₁ < 0.05*
Mean ±SD	22.0 ± 2.8	51.1 ± 6.0	43.0 ± 2.8	31.9 ± 7.8	P ₂ < 0.05*
p-value	< 0.05*				P ₃ < 0.05*
T. bilirubin (mg/dl)					P ₁ < 0.05*
Mean ±SD	0.56 ± 0.1	1.03 ± 0.15	1.6 ± 0.28	2.3 ± 0.71	P ₂ < 0.05*
p-value	< 0.05*				P ₃ < 0.05*
Albumin (gm/dl)					P ₁ < 0.05*
Mean ±SD	4.1 ± 0.15	3.2 ± 0.16	2.7 ± 0.18	2.0 ± 0.43	P ₂ < 0.05*
p-value	< 0.05*				P ₃ < 0.05*
INR					P ₁ > 0.05
Mean ±SD	1.03 ± 0.03	1.3 ± 0.15	1.3 ± 0.19	1.46 ± 0.19	P ₂ < 0.05*
p-value	< 0.05*				P ₃ < 0.05*
IMA (U/ml)					P ₁ < 0.05*
Mean ±SD	0.6 ± 0.27	0.86 ± 0.21	1.1 ± 0.45	1.56 ± 0.62	P ₂ < 0.05*
p-value	< 0.05*				P ₃ < 0.05*
IMAR					P ₁ < 0.05*
Mean ±SD	0.142±0.066	0.269±0.07	0.411±0.16	0.792±0.36	P ₂ < 0.05*
p-value	< 0.05*				P ₃ < 0.05*

P: each patient group versus control, p₁ : Child A versus Child B, p₂: Child A versus Child C, p₃: Child B versus Child C






Figure (2): IMA in studied patient groups


Table (3): Correlation co efficient between IMA & IMAR and laboratory parameters:

IMA			IMAR	
	R	P-value	R	P-value
ALT	-0.3033	0.0007*	-0.4499	< 0.0001*
AST	-0.2940	0.0011*	-0.4849	< 0.0001*
T. bilirubin	0.4357	< 0.0001*	0.5831	< 0.0001*
Albumin	-0.2559	0.0046*	-0.5987	< 0.0001*
INR	0.4368	< 0.0001*	0.2891	< 0.0013*
Hb	-0.5987	< 0.0001*	-0.5015	< 0.0001*
WBCs	-0.1527	0.0945	-0.1952	0.0319*
PLT	-0.2792	0.0019*	-0.3875	< 0.0001*


correlation between IMAR and Bilirubin




correlation between IMAR and ALT&AST




correlation between IMAR and Alb.




correlation between IMAR and INR



correlation between IMAR and WBCs



correlation between IMAR and PLT



correlation between IMAR and Hb




Figure (3): correlation coefficient between IMA and Some laboratory parameters




Figure (4): ROC curve for sensitivity and Specificity of IMA & IMAR in liver cirrhosis




Figure (5): ROC curve for sensitivity and Specificity of IMA & IMAR in Child C cirrhosis

4. CONCLUSION

IMA, IMAR levels were investigated for the first time in Egyptian patients with CLD, and it has been shown that IMA, IMAR levels were elevated in CLD. This was more pronounced in more advanced disease. Thus, they could be useful markers of assessment of liver disease severity, but this needs further investigation with wider studies using multiple serial measurements rather than a single measurement.

REFERENCES

1.Waked IA, Saleh SM, Moustafa MS, et al. High prevalence of hepatitis C in Egyptian patients with chronic liver disease. Gut 1995; 37:105-107.

2. Heidelbaugh Joel J. and Bruderly Michael: Cirrhosis and Chronic Liver Failure: Part I. Diagnosis and Evaluation. 2009 Downloaded from the American Family Physician Web site at www.aafp.org/afp. Copyright © 2006 American Academy of Family Physicians.
3. Quinlan GJ, Martin GS, Evans TW: Albumin: biochemical properties and therapeutic potential. *Hepatology* 2005, 41:1211–1219.
4. Vincent JL: Relevance of albumin in modern critical care medicine. *Best Pract Res Clin Anaesthesiol* 2009, **23**:183–191.
5. Evans TW: Review article: albumin as a drug. Biological effects of albumin unrelated to oncotic pressure. *Aliment Pharmacol Ther* 2002, **16**:S6-S11.
6. Collinson PO and Gaze DC . Ischaemia-modified albumin: clinical utility and pitfalls in measurement. *J Clin Pathol* 2008;61:1025-1028.
7. Turedi S, Cinar O, Yavuz I, et al. Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. *J Nephrol* 2010;23:335-340.
8. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes: review and clinical implications. *Clin Chem Lab Med* 2011;49:177-184.
9. Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. *Hepatology* 2009;50:555-564.
10. D. Bar-Or, E. Lau, J.V. Winkler . A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia – a preliminary report. *J. Emerg. Med.* 2000, 19: 311–315
11. Sharma R, Gaze DC, Pellerin D, et al.: Ischemia-modified albumin predicts mortality in ESRD. *Am J Kidney Dis* 2006, 47:493–502.
12. Van Belle E, Dallongeville J, Vicaut E, Degrandt A, Baulac C, Montalescot G; OPERA Investigators: Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. *Am Heart J* 2010, 159:570–576
13. Mastella AK, Moresco RN, da Silva DB, Becker AM, Duarte MM, Giovelli LL, et al (2009) Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. *Biomed Pharmacother* 2009; **63**: 762–766.
14. Valle Gottlieb MG, da Cruz IB, Duarte MM, Moresco RN, Wiehe M, Schwanke H, et al . Associations among metabolic syndrome, ischemia, inflammatory, oxidative, and lipid biomarkers. *J Clin Endocrinol Metab* 2010; **95**: 586–591.
15. Chen CY, Tsai WL, Lin PJ, Shieh SC . The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. *Clin Chem Lab Med* 2011; **49**: 1817–1821.
16. Piwowar A, Knapik-Kordecka M, Warwas M . Ischemia-modified albumin level in type 2 diabetes mellitus — Preliminary report. *Dis Markers* 2008; **24**: 311–317.
17. A.I. Ivanov, E.A. Korolenko, E.V. Korolik, S.P. Firsov, R.G. Zhabankov, M.K. Marchewka, et al. Chronic liver and renal diseases differently affect structure of human serum albumin, *Arch. Biochem. Biophys.* 408 2002; 69–77.
18. Henriksen JH, Siemssen O, Krintel JJ, Malchow-Møller A, Bendtsen F, Ring-Larsen H: Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. *J Hepatol* 2001, 34:53–60.

- 19.Cakir M, Karahan SC, Mentese A, Sag E, Cobanoglu U, Polat TB, etal. Ischemia modified albumen levels in children with chronic liver disease. Gut Liver. 2012;6(1):92-7. doi: 10.5009/gnl.2012.6.1.92. PMID:22375177
- 20.Oettl K, Stauber RE: Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. *Br J Pharmacol* 2007, 151:580–590.
- 21.Klammt S, Mitzner S, Stange J, et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end stage liver disease. *Eur J Gastroenterol Hepatol* 2007;19:257-263.
- 22.Oettl K, Stadlbauer V, Petter F, et al.: Oxidative damage of albumin in advanced liver disease. *Biochim Biophys Acta* 2008, 1782:469–473.
23. Prashanth Ashok, Kumar Subramanian and Kavitha. The Role of Ischemia Modified Albumin as a Biomarker in Patients with Chronic Liver Disease. *Journal of Clinical and Diagnostic Research*. 2016 Mar, Vol-10(3): BC09-BC12